摘要
目的:探讨盐酸莫西沙星联合康妇消炎栓治疗盆腔炎的临床疗效。方法:选取116例盆腔炎患者,随机分为对照组和治疗组,每组58例。对照组采用盐酸莫西沙星治疗;治疗组采用盐酸莫西沙星联合康妇消炎栓治疗。比较两组患者治疗前后TNF-α和CRP水平改善幅度、症状消失时间、接受临床治疗总时间、盆腔炎病情治疗效果、治疗期间药物不良反应、停止治疗后病情复发率等指标。结果:治疗后,对照组盆腔炎病情治疗总有效率为72.4%,治疗组为91.4%,两组比较差异有统计学意义(P<0.05);治疗组症状表现消失时间和接受临床治疗总时间明显短于对照组(P<0.05);治疗期间,治疗组出现药物不良反应率明显少于对照组(P<0.05);治疗组治疗前后TNF-α和CRP水平改善幅度明显大于对照组(P<0.05);停止治疗后,治疗组盆腔炎病情复发率明显低于对照组(P<0.05)。结论:盐酸莫西沙星联合康妇消炎栓治疗盆腔炎临床疗效确切,值得推广应用。
Objective： To explore the clinical effect of moxifloxacin hydrochloride combined with Kangfute inflammatory suppository in treatment of pelvic inflammatory disease.Method： One hundred and sixteen patients of pelvic inflammatory disease were randomly divided into the control group and the treatment group, each group of 58 cases. The control group was treated by moxifloxacin hydrochloride. The treatment group was treated by Kangfute inflammatory suppository combined with moxifloxacin hydrochloride. The indicators between the two groups were compared after treatment, such as the effective rate, the symptoms disappear time, total time for clinical treatment, adverse drug reactions, improved amplitude of TNF-α and CRP levels, the cessation treatment relapse rate and so on. Result：The effective rate of the control group was 72.4% while the treatment group was 91.4% after treatment, and the difference between the two groups were statistically significant（P〈0.05）. The symptoms disappear time and total time for clinical treatment of the treatment group were significantly shorter than the control group（P〈0.05）and adverse drug reactions rate during treatment of the treatment group were significantly less than the control group（P〈0.05）.The improved amplitude of TNF-α and CRP levels of the treatment group were significantly higher than the control group after treatment（P〈0.05）and the cessation treatment relapse rate of the treatment group was significantly lower than the control group（P〈0.05）.Conclusion： The clinical effect of moxifloxacin hydrochloride combined with Kangfute inflammatory suppository in treatment of pelvic inflammatory disease is excellent. It is worth popularization and application.
出处
《中国医学创新》
CAS
2013年第33期27-28,共2页
Medical Innovation of China
关键词
康妇消炎栓
盐酸莫西沙星
盆腔炎
治疗
Kangfute inflammatory suppository
Moxifloxacin hydrochloride
Pelvic inflammatory disease
Treatment
